HIV and antiretroviral therapy: Impact on the central nervous system

Progress in Neurobiology

Volumn 91, Issue 2, 2010, Pages 185-187

  Ellis, Ronald ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; HIV; NeuroAIDS

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COGNITION; DEVELOPING COUNTRY; EPILEPSY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; PANDEMIC; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; BRAIN DISEASES; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 77952291831     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2009.10.016     Document Type: Review

References (8)

1. UNAIDS.Joint United Nations Programme on HIV/AIDS Report on the Global AIDS Epidemic 2008, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland.
2. Heaton R.K., Cysique L.A., Jin H., Shi C., Yu X., Letendre S., Franklin D.R., Ake C., Vigil O., Atkinson J.H., Marcotte T.D., Grant I., Wu Z. Neurobehavioral effects of Human Immunodeficiency Virus infection among former plasma donors in rural China. J. Neurovirol. 2008, 1-14.
3. Heaton R., Franklin D., Clifford D., Woods S., Rivera-Mindt M., Vigil O., Taylor M., Marcotte T., Hampton J., Atkinson J., Grant I. HIV-associated neurocognitive impairment (NCI) remains prevalent in the era of combination antiretroviral therapy (CART): The CHARTER Study. 16th Conference on Retroviruses and Opportunistic Infections 2009, (abstract).
4. Antinori A., Arendt G., Becker J.T., Brew B.J., Byrd D.A., Cherner M., Clifford D.B., Cinque P., Epstein L.G., Goodkin K., Gisslen M., Grant I., Heaton R.K., Joseph J., Marder K., Marra C.M., McArthur J.C., Nunn M., Price R.W., Pulliam L., Robertson K.R., Sacktor N., Valcour V., Wojna V.E. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69(October 30 (18)):1789-1799.
5. Tozzi V., Balestra P., Serraino D., Bellagamba R., Corpolongo A., Piselli P., Lorenzini P., Visco-Comandini U., Vlassi C., Quartuccio M.E., Giulianelli M., Noto P., Galgani S., Ippolito G., Antinori A., Narciso P. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res. Hum. Retroviruses 2005, 21(August (8)):706-713.
6. Letendre S., Marquie-Beck J., Capparelli E., Best B., Clifford D., Collier A.C., Gelman B.B., McArthur J.C., McCutchan J.A., Morgello S., Simpson D., Grant I., Ellis R.J. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 2008, 65(January (1)):65-70. CHARTER Group.
7. Cysique L.A., Vaida F., Letendre S., Gibson S., Cherner M., Woods S.P., McCutchan J.A., Heaton R.K., Ellis R.J. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009, (May 27). [Epub ahead of print].
8. May S., Letendre S., Haubrich R., McCutchan J.A., Heaton R., Capparelli E., Ellis R. Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in NeuroAIDS. J. Neuroimmune Pharmacol. 2007, 2(1):97-104.